Foghorn Therapeutics GAAP EPS of $0.80, revenue of $83.5M
Topics: earnings GAAP EPS revenue
Read the full article at Seeking Alpha
Part of the story CSW Industrials Reports Q2 2027 Earnings Beat with Record Adjusted EBITDA (25 articles)
More World news
- Barclays Upgrades Steel Producers Cleveland-Cliffs and Reliance Amid Market Selloff
- Mercantile Bank Announces New Full-Service Banking Center in Holland, Michigan
- Broadwind Reports 48% Revenue Growth and Record Industrial Solutions Backlog in Q3 2026
- MediWound Reports Q3 2026 Financial Results Amid Clinical Trial Expansion
- Twist Bioscience Reports Q4 2026 Revenue Growth and First Positive Adjusted EBITDA
- Chicago Atlantic BDC Reports Q3 2026 Growth in Net Investment Income and Record Portfolio Value
- Google Integrates Gemini 4 Hydrogen Model into Search to Enhance Complex Query Handling
- General Motors Partners with NorthStar Clean Energy for Large-Scale Solar Project in Michigan
- CNBC Select Names Accredited Debt Relief Best for Debt Resources
- CorMedix Announces Acquisition of Heron Therapeutics Assets to Drive Revenue Growth